The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Valvular heart disease and/or dysfunction
Publications
Drug-induced valvular heart disease: an update.
Archives of cardiovascular diseases. 2013;106(5):333-9
Ergotamine-associated valvulopathy with recurrent chylous pleural effusion.
Texas Heart Institute journal. 2012;39(5):736-8
Drug-induced fibrotic valvular heart disease.
Lancet (London, England). 2009;374(9689):577-85
Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
Movement disorders : official journal of the Movement Disorder Society. 2009;24(1):129-33
Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.
Journal of internal medicine. 2008;263(1):90-8
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
The Lancet. Neurology. 2007;6(9):826-9
The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease.
Mayo Clinic proceedings. 2003;78(6):730-1
Mitral valve disease associated with long-term ergotamine use.
Southern medical journal. 1993;86(10):1179-81
Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations.
Annals of internal medicine. 1992;117(1):50-2